Gemcitabine and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Review

Ginsberg, 1997, Non-small cell lung cancer, 858 ten Bokkel Huinink, 1999, Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer, Lung Cancer, 26, 85, 10.1016/S0169-5002(99)00067-7 Cardenal, 1999, Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol, 17, 12, 10.1200/JCO.1999.17.1.12 Sandler, 2000, Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol, 18, 122, 10.1200/JCO.2000.18.1.122 Schiller, 2000, A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 19, 1a Bonomi, 1989, Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group, J Clin Oncol, 7, 1602, 10.1200/JCO.1989.7.11.1602 Carmichael, 1996, A phase I study of gemcitabine and carboplatin in non-small cell lung cancer, Semin Oncol, 23, 55 Carrato, 1998, Combination of gemcitabine (gem) and carboplatin as first line treatment in non-small cell lung cancer (NSCLC), Ann Oncol, 6, 431P Carrato, 1999, Carboplatin (CARBO) in combination with gemcitabine (GEM) in advanced non-small cell lung cancer (NSCLC). Comparison of two consecutive phase II trials using different schedules, Proc Am Soc Clin Oncol, 18, 498a Ng, 1999, A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a Hoosier Oncology Group study, Am J Clin Oncol, 22, 550, 10.1097/00000421-199912000-00003 Heching, 1999, Gemcitabine and carboplatin in advanced nonsmall cell lung carcinoma: results of a single institution phase II study, Proc Am Soc Clin Oncol, 18, 508a Jovtis, 1999, First-line therapy with gemcitabine (GEMTRO®) (G) and carboplatin (C) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II study, Proc Am Soc Clin Oncol, 18, 510a Masotti, 1999, Phase II trial of gemcitabine and carboplatin in advanced non-small cell lung cancers, Proc Am Soc Clin Oncol, 18, 517a Gross, 1999, A combination therapy of gemcitabine (GEM) and carboplatin (CBDCA) in advanced stage non-small cell lung carcinoma (NSCLC), Proc Am Soc Clin Oncol, 18, 507a Gross G, Hampton J, Kiernan H, et al. Early toxicity profile of gemcitabine/carboplatin chemotherapy with Neumega for prevention of drug-induced thrombocytopenia in advanced non-smallcell lung cancer. Proceedings of the First International Lung Cancer Congress, 2000. Edelman, 1999, Sequential carboplatin/gemcitabine (C/G) ? paclitaxel (P) in advanced non-small cell lung cancer (NSCLC): an effective and well tolerated regimen, Proc Am Soc Clin Oncol, 18, 502a Sederholm, 1999, A phase II study of gemcitabine plus carboplatin in chemonaive patients with advanced non-small cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 18, 490a Maestu, 1999, Carboplatin and gemcitabine in elderly patients with advanced non small cell lung cancer: preliminary results, Eur J Cancer, 35, 1040 Iaffaioli, 1999, Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer, J Clin Oncol, 17, 921, 10.1200/JCO.1999.17.3.921 National Cancer Institute. Common Toxicity Criteria, Version 2.0, 1999. Martinez, 1998, Gemcitabine plus carboplatin in advanced nonsmall cell lung cancer (NSCLC): a phase I trial, Proc Am Soc Clin Oncol, 17, 494a